Abstract:Schematic of the study illustrating the advantages of procyanidin B1 in penetrating the blood–brain barrier and its potential in inhibiting glioblastoma (GBM). Mechanistically, procyanidin B1 binds to NRF2 and inhibits its expression through a ubiquitin‐dependent protein catabolic process mediated by PSMC3. Additionally, procyanidin B1 reduces concentrations of NADPH and GSH and induces H2O2 overload to increase lipid peroxide levels via downregulation of NRF2. Procyanidin B1 also alters the expression of two key genes, COX2 and SLC7A11, associated with ferroptosis and promotes the key marker (TFR1, the transferrin receptor) of ferroptosis in GBM. BBB: blood–brain barrier; GSH: glutathione; NADPH: nicotinamide adenine dinucleotide phosphate; GBO: glioblastoma organoid; LOOH: lipid hydroperoxide. The Schematic was partly adapted from BioRender.com with permission. NRF2 signaling is a crucial antioxidant defense mechanism against ferroptosis in tumors, and targeting NRF2 is essential for tumor therapy. However, the effectiveness of NRF2 inhibitors remains unexplored. The active ingredients of traditional Chinese medicine serve as important sources of NRF2 inhibitors. In this study, we established an intracranial glioblastoma (GBM) orthotopic model and observed the effects of procyanidin B1 on tumor growth and ferroptosis. Using protein‐small‐molecule docking, z‐stack assay of laser confocal imaging, surface plasmon resonance assay, immunoprecipitation, mass spectrometry, and western blotting, we detected the binding between procyanidin B1 and NRF2 and the effect of PSMC3 on the ubiquitin‐dependent degradation of NRF2 in GBM cells. Our results showed that procyanidin B1 acted as a novel NRF2 inhibitor to suppress GBM cell proliferation and prolonged the survival of GBM‐bearing mice; it also mediated the interaction between PSMC3 and NRF2 to promote ubiquitin‐dependent protein degradation of NRF2, which induced ferroptosis in GBM cells. In addition, we found that procyanidin B1 enhanced H2O2 accumulation by downregulating NRF2 during ferroptosis in GBM cells. The botanical agent procyanidin B1 induced ferroptosis and exerted anti‐tumor effects through PSMC3‐mediated ubiquitin‐dependent degradation of NRF2 proteins, providing a potential drug candidate for adjuvant therapy in patients with GBM.

Procyanidin B1 Promotes PSMC3‐NRF2 Ubiquitination to Induce Ferroptosis in Glioblastoma

NIR-promoted Ferrous Ion Regeneration Enhances Ferroptosis for Glioblastoma Treatment.

Catalytic nanoreactors promote GLUT1-mediated BBB permeation by generating nitric oxide for potentiating glioblastoma ferroptosis

Targeting SIRT3 sensitizes glioblastoma to ferroptosis by promoting mitophagy and inhibiting SLC7A11

HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis

Ginsenoside Rg5 inhibits glioblastoma by activating ferroptosis via NR3C1/HSPB1/NCOA4

Intracellular C5aR1 inhibits ferroptosis in glioblastoma through METTL3-dependent m6A methylation of GPX4

Biomimetic Macrophage Membrane-Camouflaged Nanoparticles Induce Ferroptosis by Promoting Mitochondrial Damage in Glioblastoma

Down-regulated BNC1 Promotes Glioma by Inhibiting Ferroptosis Via TCF21/PI3K Signaling Pathway BNC1TCF21PI3K

A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma

Autophagy-dependent ferroptosis as a potential treatment for glioblastoma

Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma

Fucoxanthin triggers ferroptosis in glioblastoma cells by stabilizing the transferrin receptor

An Intelligent Nanoplatform for Orthotopic Glioblastoma Therapy by Nonferrous Ferroptosis

Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting Sirna from Iron Oxide Nanoparticles.

Induction of Non-Canonical Ferroptosis by Targeting Clusters Suppresses Glioblastoma

Longikaurin A Induces Ferroptosis and Inhibits Glioblastoma Progression Through DNA Methylation - Mediated GPX4 Suppression

Iron oxide nanoparticles loaded with paclitaxel inhibits glioblastoma by enhancing autophagy-dependent ferroptosis pathway

Inhibition of Glycolytic Metabolism in Glioblastoma Cells by Pt3glc Combinated with PI3K Inhibitor Via SIRT3-mediated Mitochondrial and PI3K/Akt-MAPK Pathway

Postoperative Injection of a Triptolide‐Preloaded Hydrogel Prevents the Recurrence of Glioblastoma by Dual‐Pathway Activation of Ferroptosis

NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation